Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Dr. Lorianne Masuoka MD Joins The Biotech That The FDA & Media Are Romancing

|Includes: InVivo Therapeutics Holdings Corp (NVIV)

CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (NVIV) today announced the appointment of Lorianne Masuoka, MD, as Chief Medical Officer (NYSE:CMO), effective March 2, 2015. She will be taking over for the interim CMO, Lou Vaickus, MD, who is also Founder & President of akta Pharmaceutical Development LLC, a life sciences consulting company.

Prior to joining the InVivo team, Dr. Masuoka served as Senior Vice President and Chief Medical Officer at Cubist Pharmaceuticals from July 2013 until Jan 2015. As a member of Cubist's executive management team, she managed over 150 employees in the areas of clinical research, drug safety, biostatistics and data management, and clinical operations. Prior to her time at Cubist, she served in various roles of increasing responsibility at Nektar Therapeutics, including Senior Vice President and Chief Medical Officer from August 2008 until August 2011. Dr. Masuoka served as Vice President, Clinical Development at FivePrime Therapeutics from July 2003 until August 2008. Prior to that, she served as Director, Clinical Development, Oncology at Chiron.

Dr. Masuoka has a medical degree from the University of California, Davis, where she also completed her residency in neurology. She completed her epilepsy fellowship at Yale University and has a board certification from the American Board of Psychiatry and Neurology (Neurology).

Mark Perrin, CEO and Chairman of the Board, said, "I am very pleased to have Lorianne joining the InVivo team at such an exciting time in our company's history. She will be instrumental as we transition from executing on the expedited timeline for our pilot study to designing our pivotal study. Her medical background in neurology and extensive experience in clinical development, managing early to late stage clinical trials in neurological indications and many other multidisciplinary indications will make her an invaluable asset as we move forward with our current and future clinical programs.... Ella Ruth Comments Below

There is scientific justification for the FDA and media to both converge on Invivo (OTCMKTS:NVIV), I mean this technology literally is causing crippled people to walk. It has propelled science into a real that not many years ago was viewed as entirely metaphysical,miraculous and empirically unreachable.

Invivo is able to take a miniature medical device no larger than a TIC TAC with a little biomaterial putty an heal a morbidly damaged spinal cord. Look at the below

Dr Masuoka provides a major portion of the corporate intelligentsia and culture to take the company forward through to commercialization.

I doubt if this technology will have to have all four stages before it passes into commercialization.

I am speculative and long!

Additional disclosure: I am long